Receipt of guideline‐concordant local and chemotherapy‐based systemic therapy for patients with triple‐negative breast cancer: 10‐year survival outcomes in a multi‐state population‐based analysis

Women diagnosed with triple‐negative (ER‐, PR‐, HER2‐) breast cancer (TNBC) have poor survival outcomes compared with other breast cancer subtypes. Yet there is little nonexperimental data on whether guideline‐concordant therapy translates to better outcomes over time, or about factors associated with receipt of such guideline care. This study addresses these issues.

• Publication year

  2026

• Venue

  Cancer

• Publication date

  2026-02-15

• Fields of study

  Medicine

• Identifiers
  DOI 10.1002/cncr.70267PMID 41701617PMCID PMC12980793
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• Trends and Disparities in the Use of Immunotherapy for Triple-Negative Breast Cancer in the US

  2025cited by this paper
• Overall Survival with Pembrolizumab in Early-Stage Triple-Negative Breast Cancer.

  2024cited by this paper
• Breast Cancer, Version 3.2024, NCCN Clinical Practice Guidelines in Oncology.

  2024cited by this paper
• Clinical trials of immunotherapy in triple-negative breast cancer

  2022cited by this paper
• Use of Immune Checkpoint Inhibitor Pembrolizumab in the Treatment of High-Risk, Early-Stage Triple-Negative Breast Cancer: ASCO Guideline Rapid Recommendation Update.

  2022cited by this paper
• Cancer Treatment Data in Central Cancer Registries: When Are Supplemental Data Needed?

  2022cited by this paper
• Integrating Immunotherapy Into the Treatment Landscape for Patients With Triple-Negative Breast Cancer.

  2022cited by this paper
• Evaluation of Racial/Ethnic Differences in Treatment and Mortality Among Women With Triple-Negative Breast Cancer.

  2021cited by this paper
• Update on triple‐negative breast cancer disparities for the United States: A population‐based study from the United States Cancer Statistics database, 2010 through 2014

  2019cited by this paper
• Unlocking the potential of population‐based cancer registries

  2019cited by this paper
• Triple-negative breast cancer has worse overall survival and cause-specific survival than non-triple-negative breast cancer

  2016cited by this paper
• Age-Related Disparity in Immediate Prognosis of Patients with Triple-Negative Breast Cancer: A Population-Based Study from SEER Cancer Registries

  2015cited by this paper
• Breast cancer survival in African-American women by hormone receptor subtypes

  2015cited by this paper
• Adherence to treatment guidelines and survival in triple-negative breast cancer: a retrospective multi-center cohort study with 9156 patients

  2013influential reference
• The table 2 fallacy: presenting and interpreting confounder and modifier coefficients.

  2013cited by this paper
• Challenges of guarantee-time bias.

  2013cited by this paper
• The Use and Interpretation of Competing Risks Regression Models

  2012cited by this paper
• Landmark Analysis at the 25-Year Landmark Point

  2011cited by this paper
• Quality of cancer registry data: findings from CDC-NPCR's Breast and Prostate Cancer Data Quality and Patterns of Care Study.

  2011cited by this paper
• Meta‐analysis of brain‐derived neurotrophic factor p.Val66Met in adult ADHD in four European populations

  2010cited by this paper
• Competing risk regression models for epidemiologic data.

  2009cited by this paper
• Immortal person-time in studies of cancer outcomes.

  2009influential reference
• Race and triple negative threats to breast cancer survival: a population-based study in Atlanta, GA

  2008cited by this paper
• Survival difference between non-Hispanic black and non-Hispanic white women with localized breast cancer: the impact of guideline-concordant therapy.

  2008cited by this paper
• Descriptive analysis of estrogen receptor (ER)‐negative, progesterone receptor (PR)‐negative, and HER2‐negative invasive breast cancer, the so‐called triple‐negative phenotype

  2007cited by this paper
• Breast Cancer Staging: Working With the Sixth Edition of the AJCC Cancer Staging Manual

  2006cited by this paper
• Update: NCCN breast cancer clinical practice guidelines.

  2004cited by this paper
• Update: NCCN breast cancer Clinical Practice Guidelines.

  2004cited by this paper
• NCCN breast cancer clinical practice guidelines in oncology: an update.

  2003cited by this paper
• AJCC Cancer Staging Manual. 6th ed

  2002cited by this paper
• AJCC Cancer Staging Manual

  2002cited by this paper
• Adjuvant therapy of primary breast cancer: a review of key findings from the 7th international conference, St. Gallen, February 2001.

  2001cited by this paper
• Regression Modeling Strategies: With Applications to Linear Models, Logistic Regression, and Survival Analysis

  2001cited by this paper
• A Proportional Hazards Model for the Subdistribution of a Competing Risk

  1999cited by this paper
• Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group.

  1998cited by this paper
• NATIONAL CANCER INSTITUTE

  1993cited by this paper
• Applied Logistic Regression, Second Edition

  1989cited by this paper
• Statistical Primer for Cardiovascular Research Introduction to the Analysis of Survival Data in the Presence of Competing Risks

  year unknowncited by this paper

• No citing papers are available for this paper.